Search Within

Early Drug Development Service

Formats
  1. Meeting Abstract (234)
  2. Journal Article (209)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (461)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (244)
  4. Department of Pathology and Laboratory Medicine (200)
  5. Human Oncology and Pathogenesis Program (193)
  6. Gynecologic Medicine Service (186)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (123)
  3. Alexander Drilon (111)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (6)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (111)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (23)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (126)
  2. American Association for Cancer Research (101)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (461)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A.; Hong, D.; Deeken, J.; Smith, S.; Reynolds, M.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors
    Meeting Abstract

    Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors
    Meeting Abstract

    Hyman, D.; Chatterjee, M.; Langenberg, M. H. G.; Lin, C. C.; Suarez, C.; Tai, D.; Cassier, P.; Yamamoto, N.; De Weger, V. A.; Jeay, S.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy
    Meeting Abstract

    Scaltriti, M.; Carmona, F. J.; Toska, E.; Cocco, E.; Hyman, D.; Cutler, R.; Avogadri-Connors, F.; Wick, M. J.; Papadopoulos, K. P.; Lalani, A. S.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies
    Journal Article

    Momtaz, P.; Pentsova, E.; Abdel-Wahab, O.; Diamond, E.; Hyman, D.; Merghoub, T.; You, D.; Gasmi, B.; Viale, A.; Chapman, P. B.
    Oncotarget (2016)

    Fulltext@MSK | Save
  • Picking the right patient for human epidermal growth factor receptor 3 - Targeted therapy in platinum-resistant ovarian cancer
    Journal Article

    Schram, A. M.; Iasonos, A.; Hyman, D. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family
    Journal Article

    Yang, C.; Arnold, A. G.; Trottier, M.; Sonoda, Y.; Abu-Rustum, N. R.; Zivanovic, O.; Robson, M. E.; Stadler, Z. K.; Walsh, M. F.; Hyman, D. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT
    Journal Article

    Ulaner, G. A.; Hyman, D. M.; Ross, D. S.; Corben, A.; Chandarlapaty, S.; Goldfarb, S.; McArthur, H.; Erinjeri, J. P.; Solomon, S. B.; Kolb, H.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease
    Journal Article

    Diamond, E. L.; Hatzoglou, V.; Patel, S.; Abdel-Wahab, O.; Rampal, R.; Hyman, D. M.; Holodny, A. I.; Raj, A.
    Orphanet Journal of Rare Diseases (2016)

    Fulltext@MSK | Save
  • Automated eligibility screening and monitoring for genotype-driven precision oncology trials
    Journal Article

    Eubank, M. H.; Hyman, D. M.; Kanakamedala, A. D.; Gardos, S. M.; Wills, J. M.; Stetson, P. D.
    Journal of the American Medical Informatics Association (2016)

    Fulltext@MSK | Save